癌免疫療法市場:現在の分析と予測2021-2027年
PR TIMES / 2021年11月22日 19時45分
UnivDatos Market Insights (UMI)、は調査レポート「癌免疫療法市場;世界的な機械分析」2021年11月 21日 に発刊しました。レポートは、企業概要 、製品種類、販売量 、市場規模 、メーカ概要 、市場シェア 、などが含まれています。
調査レポートについてーhttps://univdatos.com/report/cancer-immunotherapy-market/
Traditional cancer treatments are still the most practiced and the most standard treatment of medical anti-cancer strategies. While they include surgery, chemotherapy, and radiation therapy, cancer immunotherapy is gaining increasing acceptance and is emerging as a new approach that has recently been revolutionized and just approved. In early 2018, approximately 32 monoclonal antibodies were approved by the FDA or EMA for cancer indications and cancer immunotherapy for medical purposes. The surge in cancer incidence and the growing population of the elderly are expected to boost market growth.
[画像: https://prtimes.jp/i/88385/19/resize/d88385-19-705fa10adfa44550c495-0.png ]
In 2020, an estimated 19.3 million new cancer cases (18.1 million excluding non-melanoma skin cancer) will be diagnosed worldwide and approximately 10 million cancer deaths (9.9 million excluding non-melanoma skin cancer). People) are expected. Breast cancer in women is the most diagnosed cancer, surpassing lung cancer, with an estimated 2.3 million new cases (11.7%), lungs (11.4%), colonic rectum (10.0%), prostate (7.3%), and stomach. I have (5.6%) cancer.
Sample reports over https://univdatos.com/get-a-free-sample-form-php/?product_id=5089
eligibility and reactivity of the AlysonHaslam and VinayPrasad was carried out in 2019 "checkpoint inhibitors immunotherapeutic agents According to a study entitled "Estimating the Percentage of Cancer Patients in the United States," the estimated proportion of cancer patients eligible for checkpoint inhibitors in the United States was 1.54% in 2011, compared to an estimated 26.86 in 2015. %, Increased to 43.63% in 2018. In addition, NSCLC (21.48%), hepatocellular carcinoma (4.95%), and SCLC were the diseases that contributed most to the eligibility calculation (3.79%). In 2016, immunotherapy treatment accounted for 33% of oncology drug spending, even though it accounted for only 9% of FDA-approved oncology drugs. All major oncology drug companies are building strong immunotherapy pipelines to increase M & A and investor interest.
Key players
in the key player market include AbbVie, Amgen, AstraZeneca, bluebird bio, Bristol-Myers Squibb, F. Hoffmann-La Roche, Janssen Biotech, Merck, Novartis, Pfizer and more.
Description of Market Segmentation The
market is the type of treatment (monoclonal antibodies, vaccines, checkpoint inhibitors, cell therapies, immune system modulators, adoptive cell transfer, cytokines, etc.), applications (lung cancer, breast cancer, colorectal cancer, melanoma, prostate cancer). , Head and neck cancer, etc.), end users (cancer specialists / research centers, hospitals and clinics), and regions / countries provide insights into segments such as.
The monoclonal antibody segment occupies a major share of the treatment. "
Based on the type of treatment, the market monoclonal antibodies, vaccines, checkpoint inhibitors, cell therapy, immune system modulators, adoptive cell transplantation, has been subdivided, such as cytokines. The monoclonal antibody segment dominated the market with a 37.3% share in 2020
"Among the applications, breast cancer is expected to grow at the largest CAGR during the analysis period"
Further based on the application, the market is lung cancer, breast cancer , Colonic rectal cancer, melanoma, prostate cancer, head and neck cancer, and other cancer applications. By 2020, lung cancer will have the largest market revenue share of 25.5% and is expected to dominate the market during the forecast period.
The report covers North America (US, Canada, other North America), Europe (Germany, UK, Russia, France, Spain, other Europe), Asia Pacific (China, Japan, India, Australia, other APAC), and others. Provides a detailed analysis of major regions and countries, including the world.
North America dominated the market and generated US $ 37.56 billion in revenue in 2020. In the United States, approximately 1.9 million new cancer cases are expected to be diagnosed in 2021. It is estimated that approximately 608,570 Americans will die of cancer in 2021, which is equivalent to approximately 1,670 deaths per day. Cancer is the second leading cause of death in the United States, with only heart disease surpassing it.
Reasons to Buy this Report:
· This survey includes market size and forecast analysis validated by key certified industry experts
· The report provides a quick overview of industry-wide performance
· The report covers a detailed analysis of peers in prominent industries with a major focus on key business finances, product portfolios, expansion strategies, and recent developments.
· Popular drivers in the industry . , Constraints, Key Trends, and Opportunities Detailed Survey
· This study comprehensively covers markets across different segments
· Detailed country-level analytical
research reports for the industry- https: // univdatos. com / report / cancer-immunotherapy- market /
sample report over https://univdatos.com/get-a-free-sample-form-php/?product_id=5089
Company Profile
UnivDatos Market Insights (UMI), a subsidiary of Universal Data Solutions, is a fast-growing, dynamic market research company led by a core of dedicated professionals. We provide our clients with sustainable strategies to shape their future business strategies. It provides customized reports, consulting services, and syndicated reports to help aspiring changemakers make wise strategic decisions. Our team of expert analysts critically assess market dynamics, demonstrate competitive intelligence from hard-working sources, and deepen client understanding across a variety of industries.
企業プレスリリース詳細へ
PR TIMESトップへ
この記事に関連するニュース
-
最先端テクノロジーの祭典「SXSW 2024」にICMG Next CEOのAna Arriola-Kanadaがスピーカーとして登壇
PR TIMES / 2024年3月26日 18時45分
-
Hyperithm、機関投資家向けのデジタル資産デリバティブ取引プラットフォームを開発する「Kemet」に出資
PR TIMES / 2024年3月26日 10時45分
-
期末配当予想の修正 (復配) に関するお知らせ<English Follows>
PR TIMES / 2024年3月21日 14時45分
-
規模、シェア、成長、傾向、機会、予測による非薬物うつ病治療市場分析(2023年から2030年)
@Press / 2024年3月14日 21時50分
-
Hyperithm、イーサリアムベースのトークン・ストリーミング・プロトコル「Superfluid」に出資
PR TIMES / 2024年3月6日 10時45分
ランキング
-
1「残念なセルフレジ」はなぜ生まれるのか 顧客体験を損なわない方法
ITmedia ビジネスオンライン / 2024年3月28日 7時0分
-
2ファミリーマート、商品に小林製薬「紅麹」使用でお詫び・売場から撤去 「ビビンバ炒飯&サムギョプサル」など3商品【一覧】
ORICON NEWS / 2024年3月28日 18時20分
-
3LINEヤフーに管理改善勧告 個人情報保護委、「不備」と認定
共同通信 / 2024年3月28日 16時5分
-
4サプリ摂取、新たに2人死亡確認 紅こうじ使用、死者計4人に
共同通信 / 2024年3月28日 12時41分
-
5サイゼリヤ会長が「どうしてうちの料理はこんなに高くてまずいのか」と真剣に悩んでいる理由
プレジデントオンライン / 2024年3月27日 17時15分
記事ミッション中・・・
記事にリアクションする
記事ミッション中・・・
記事にリアクションする
エラーが発生しました
ページを再読み込みして
ください